About Decina Pharma
Decina Pharma offers products and services including Pharmaceutical API and Formulations.
- SectorsHealthcare
- Legal Name Decina Pharma Pvt. Ltd.
- Date of Incorporation 20 Apr, 2017
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹1.73 Cr
FY 2025 · -51% YoY
- Net Loss-₹30.5 Lakh
FY 2025 · -18% margin
- EBITDA-₹19.2 Lakh
FY 2025 · -11% margin
Associated legal entities of Decina Pharma
Decina Pharma operates through Decina Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Decina Pharma Private Limited CIN U51909PN2017PTC170011 | Active | 20 Apr 2017 | Pune, Maharashtra | ₹1.7 Cr | – | 2 | View details |
Products & Services of Decina Pharma
Decina Pharma offers a comprehensive portfolio of products and services, including Pharmaceutical API and Formulations.
Active pharmaceutical ingredients are supplied for medical applications through established partnerships.
Formulations are provided as part of an integrated portfolio covering various products and services.
Board of directors of Decina Pharma Private Limited (Decina Pharma)
Decina Pharma Private Limited is the primary company behind Decina Pharma. The board of Decina Pharma Private Limited currently have 2 directors; the longest-serving is Sherrin Pulikathotil James, appointed in 2017. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sherrin Pulikathotil James DIN 07430399 | Director | 20 Apr 2017 | 9 yrs 5 mo | Decina Pharma Private Limited |
| Jaji Puthen Parambil James DIN 07765154 | Director | 20 Apr 2017 | 9 yrs 5 mo | Decina Pharma Private Limited |
Financials of Decina Pharma
Figures of Decina Pharma Private Limited, the primary company behind Decina Pharma, for FY 2025. Revenue was ₹1.73 Cr (-51% year on year). Net loss was -₹30.5 Lakh (-18% margin). EBITDA was -₹19.2 Lakh (-11% margin). Revenue has grown at a compounded annual rate of -7% over three years and -1% over five years.
- ₹1.73 CrRevenue · FY 2025 · -51% YoY
- -₹30.5 LakhNet loss · -18% margin
- -₹19.2 LakhEBITDA · -11% margin
- ₹1 LakhPaid-up capital
- -7%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Decina Pharma Private Limited are on its company page.
Detailed financial statements for Decina Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Decina Pharma
10 companies that operate in the same segment as Decina Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Decina Pharma
The primary company behind Decina Pharma, Decina Pharma Private Limited, reported revenue of ₹1.73 Cr for FY 2025, down 51% year on year.
Decina Pharma is established to develop expertise in global pharmaceutical API and formulations, partnering with around 1500 companies in pharmaceuticals, cosmeceuticals, nutraceuticals, and intermediates. Credibility is built through best-in-class supply chain management and on-time delivery, with recognition as a leading organization offering a wide portfolio from basic chemicals to sophisticated molecules. Operations are conducted in multiple countries, emphasizing WHO-GMP approved facilities and a commitment to quality, integrity, and innovation.
Decina Pharma offers Pharmaceutical API and Formulations.
Decina Pharma operates through Decina Pharma Private Limited.
The legal entities of Decina Pharma currently have 2 directors, including Sherrin Pulikathotil James, Jaji Puthen Parambil James.